Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...
The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ...
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...
1d
Zacks.com on MSNAlnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results